Retrospective Study

Geographical distribution of the incidence of gastric cancer in Bhutan

Tashi Dendup, James M Richter, Yoshio Yamaoka, Kinley Wangchuk, Hoda M Malaty

Tashi Dendup, Department of Surgery, Jigme Dorji Wangchuck National Referral Hospital, Thimphu, Bhutan

James M Richter, Massachusetts General Hospital, Harvard Medical School, MGH Gastroenterology Associates, Harvard University, Boston, MA 02114, United States

Yoshio Yamaoka, Department of Environmental and Preventive Medicine, Oita University Faculty of Medicine, Yufu 879-5593, Japan

Kinley Wangchuk, Microbiology Unit, Department of Laboratory Medicine, Jigme Dorji Wangchuck National Referral Hospital, Thimphu, Bhutan

Hoda M Malaty, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, United States

Author contributions: Dendup T and Malaty HM contributed equally to this work; Malaty HM and Dendup T designed research; Malaty HM, Richter JM, Yamaoka Y and Wangchuk K performed research and contributed new reagents/analytic tools; and Malaty HM analyzed data and wrote the paper.

Supported by The Center for Eye Research and Education, Boston Massachusetts (partly).

Institutional review board statement: The project was approved by National Referral Hospital, Thimphu.

Informed consent statement: This is a retrospective Study used data for the analysis.

Conflict-of-interest statement: There is no any conflict of interest to any of the contributed authors.

Data sharing statement: Excel file of data is attached.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Hoda M Malaty, MD, PhD, Department of Medicine, Baylor College of Medicine, Houston, Veterans Affairs Medical Center (111D), 2002 Holcombe Blvd., Houston, TX 77030, United States. hmalaty@bcm.edu
Telephone: +1-713-7950232

Received: March 22, 2015
Peer-review started: March 23, 2015
First decision: April 23, 2015
Revised: May 9, 2015
Accepted: August 31, 2015
Article in press: August 31, 2015
Published online: October 14, 2015

Abstract

AIM: To estimate the prevalence of gastric cancer (GC) in a cohort of patients diagnosed with GC and to compare it with patients diagnosed with all other types of gastro-intestinal (GI) cancer during the same period.

METHODS: Between 2008 and 2013, five-year period, the medical records of all GI cancer patients who underwent medical care and confirm diagnosis of cancer were reviewed at the National Referral Hospital, Thimphu which is the only hospital in the country where surgical and cancer diagnosis can be made. Demographic information, type of cancer, and the year of diagnosis were collected.

RESULTS: There were a total of 767 GI related cancer records reviewed during the study period of which 354 (46%) patients were diagnosed with GC. There were 413 patients with other GI cancer including; esophagus, colon, liver, rectum, pancreas, gall bladder, cholangio-carcinoma and other GI tract cancers. The GC incidence rate is approximately 0.9/10000 per year (367 cases/5
years per 800000 people). The geographic distribution of GC was the lowest in the south region of Bhutan 0.3/10000 per year compared to the central region 1.4/10000 per year, Eastern region 1.2/10000 per year, and the Western region 1.1/10000 per year. Moreover, GC in the South part was significantly lower than the other GI cancer in the same region (8% vs 15%; OR = 1.8, 95%CI: 1.3-3.1, \( P = 0.05 \)). Among GC patients, 38% were under the age of 60 years, mean age at diagnosis was 62.3 (± 12.1) years with male-to-female ratio 1:0.5. The mean age among patients with all other type GI cancer was 60 years (± 13.2) and male-to-female ratio of 1:0.7. At time of diagnosis of GC, 342 (93%) were at stage 3 and 4 of and by the year 2013; 80 (23%) GC patients died compared to 31% death among patients with the all other GI cancer (\( P = 0.08 \)).

CONCLUSION: The incidence rate of GC in Bhutan is twice as high in the United States but is likely an underestimate rate because of unreported and undiagnosed cases in the villages. The high incidence of GC in Bhutan could be attributed to the high prevalence of Helicobacter pylori infection that we previously reported. The lowest incidence of GC in Southern part of the country could be due to the difference in the ethnicity as most of its population is of Indian and Nepal origin. Our current study emphasizes on the importance for developing surveillance and prevention strategies for GC in Bhutan.

Key words: Gastric cancer; Mortality; Epidemiology; Bhutan

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: The incidence rate of gastric cancer (GC) in Bhutan is twice as high in the United States but is likely an underestimate rate because of unreported and undiagnosed cases in the villages. The high incidence of GC in Bhutan could be attributed to the high prevalence of Helicobacter pylori infection that we previously reported. The lowest incidence of GC in Southern part of the country could be due to the difference in the ethnicity as most of its population is of Indian and Nepal origin. Our current study emphasizes on the importance for developing surveillance and prevention strategies for GC in Bhutan.

INTRODUCTION

Gastric cancer (GC) is the second leading cause of cancer-related mortality and the fourth most common cancer globally\(^1\)\(^-\)\(^3\). However, its incidence rates in different geographical regions are distinctly varied\(^2\).

It been reported that in East Asia, high-risk countries include South Korea, Japan and China, where the age-standardized incidence rate is higher than 20 cases of GC per 100000 inhabitants per year\(^2\). The World Health Organization reports the incidence of GC in Bhutan to be very high\(^4\); however there is no published data yet. Bhutan is a small mountainous country bordering India and China and consists of four geographical regions, west, east, central, and south with a population consists of 800000 citizens.

It has been established that a Helicobacter pylori (H. pylori) infection is an etiologic agent of chronic gastritis and peptic ulcer disease, GC and mucosal associated lymphoid tissue lymphoma (MALT) and it is listed as a number one carcinogen\(^5\)\(^-\)\(^8\). We previously reported a very high prevalence of H. pylori in Bhutan\(^9\)\(^,\)\(^10\). Childhood hygiene practices and family education determine the prevalence of H. pylori infection\(^11\)\(^,\)\(^12\). The current study aimed to estimate the incidence of GC in Bhutan and to compare the geographic distribution of GC to our previously reported geographic distribution of H. pylori infection.

MATERIALS AND METHODS

Data source and case identification

Between 2008 and 2013, five-year period, the medical records of all Gastro-Intestinal Cancer patients who underwent medical care and confirm diagnosis of cancer were reviewed at the National Referral Hospital, Thimphu which is the only hospital in the country where surgical and cancer diagnosis can be made. Diagnosis and ascertainment of the GC cases was based on endoscopic and pathological examination. There is only one surgeon in the country (TD) who operates on most/all the oncology cases in the country and there not yet established GC registry in Bhutan. Demographic information, e.g., age, gender, place of residence, and date of diagnosis were collected. For each patient, type of gastro-intestinal cancer was retrieved.

Geography, population, and climate of Bhutan

Bhutan is a remote Himalayan country between India and Tibet (China) with a population consists of only 800000 citizens residing in 18147 sq mi (47000 sq km) (Figure 1). Seventy percent of country is rural and agriculture based and the literacy rate is 47% (2011...
More than 30% of Bhutan populations live below poverty level. The climate in Bhutan varies with elevation, from subtropical in the south to temperate in the highlands and polar-type climate, with year-round snow in the north.

Bhutan is demographically divided into four main regions, Southern, Western, Eastern, and central regions. The Southern region shares border with India and ethnically they are of Indian and Nepal origin. The Western region is mostly on higher altitudes and socioeconomic standard is higher than Southern region. The normal water supply is through rural water scheme that is supported by the government and most people use local streams, rivers and piped water supply. The Central region shares similarity with the Western region both socioeconomically and geographically though it is little warmer. The Eastern region is lower in altitude than the Western region and have similar rural water supply scheme as the Western region.

**Statistical analysis**

Calculation of the crude incidence rate was based on the number of recorded cases divided by the overall population by the number of years. The estimated Bhutan population in 2005 was 800000.

**RESULTS**

There were a total of 767 GI related cancer records reviewed during the years of 2008 and 2013. There were 354 (46%) patients diagnosed with GC and 413 patients with diagnosed with esophagus, colon, liver, rectum, pancreas, gall bladder, cholangio-carcinoma and other types of GI cancers. The GC incidence rate was approximately 0.9/10000 per year (354 cases/5 years/800000 people). Among GC patients, 38% were under the age of 60 years, mean age at diagnosis was 62.3 (SD ± 12.1) years and the male-to-female ratio 1:0.5. The mean age among patients with all other type GI cancer was 60 years (± 13.2) and male-to-female ratio of 1:0.7. GC in the South part was significantly lower than the other GI cancer in the same region (8% vs 15%, OR = 1.8, 95%CI: 1.3-3.1, P = 0.05).

The geographic distribution of the overall number of GC cases by each city is presented in Figure 1. We calculated the incidence rate of GC by each region; we found that the geographic distribution of GC was the lowest in the Southern region of Bhutan 0.3/10000 per year compared to the central region 1.4/100000 per year, Eastern region 1.2/10000 per year, and the Western region 1.1/10000 per year (Figure 2). As we previously reported, the geographic distribution of *H. pylori* infection was the lowest in the south region of the country (Figure 3).

At time of diagnosis of GC, 10 (3%) of the patients were at stage 1, 15 (4%) at stage 2, 211 (60%) at stage 3 and 118 (33%) stage 4. By the year 2013; 79 GC patients (22%) died.

**DISCUSSION**

The latest estimate of the global incidence rates of GC was updated by the International Agency for Research on Cancer in 2008 report estimated that there were 989000 new cases of GC or (7.8% of all reported cancer cases)\[1-3\]. We found that the incidence rate
of GC in Bhutan is high as it is second higher rate of cancer in the country after the incidence of cervical cancer (Unpublished data). The results of the current study add more emphasis to literature of the high GC incidence rate in South Asia, as the current study is the first report of the incidence of GC in Bhutan.

In our previous study in Bhutan when we assessed subjects for gastric mucosal atrophy, we found that PG I/II ratio was significantly inversely correlated with the atrophy score in the antrum and the corpus. Furthermore, we found that the PG status was significantly associated with the presence of atrophy in the corpus and the prevalence of the PG-positive status was significantly higher among H. pylori-positive subjects than among H. pylori-negative subjects. We concluded that the high incidence of GC in Bhutan can be attributed to the high prevalence of H. pylori infection and gastric mucosal atrophy[13].

Geographic variations in GC incidence have been reported in both the West and the East[14-16]. Of interest our results revealed the lowest GC rate was found in south Bhutan than the rest of the country. This variation is consistent with our previous published results of the finding of the lowest H. pylori prevalence in the south part Bhutan[9]. The marked lower prevalence in the Southern region could be due is the different of the ethnicity in the region as they are of Indian and Nepal origin and they have different food habits than the original Bhutanese. It is known that Bhutanese are broadly from three ethnic backgrounds. The first ethnic group is from Tibetan descent that mainly from the Western parts of the country while the second is the Indo-Burmese ethnic group where mostly from the population in the Eastern parts of the country, the Southern Bhutanese, the third group, is of the Nepali origin and mainly Aryan descent. Migration studies have shown that first-generation migrants from countries with a high incidence of H. pylori infection relocating to countries of low incidence rates had similar risks as that of the country of origin, but the incidence rate tended toward that of the host country in subsequent generations, suggesting the important role of environmental risk factors[17-20]. Moreover, various biological strains could be present in different geographical locations of Bhutan.

Figure 2  Gastric cancer cases distribution by area in Bhutan.

Figure 3  Geographic distribution of the incidence of gastric cancer and Helicobacter pylori infection.
parts of the country and within individuals. A study published that Indian *H. pylori* isolates have been shown to have European origins and are widely held to be only mildly pathogenic[21].

The high incidence of GC in Bhutan could be attributed to the high prevalence of *H. pylori* infection that we previously reported. Moreover, it was also reported that host genetic have an impact on host responses to gastric inflammation and acid secretion, thereby interacting with *H. pylori* infection in gastric carcinogenesis. Therefore, host genetic factors may determine why some individuals infected with *H. pylori* develop GC, while others do not[22].

It has been established that a *H. pylori* infection is an etiologic agent of chronic gastritis and peptic ulcer disease, GC and MALT and it is listed as a number one carcinogen[23-4]. Several studies and randomized controlled trials showed that *H. pylori* eradication reduce GC incidence by at least 35%[23-28]. Current consensus is that *H. pylori* screening and treatment is effective only in high-risk populations[29-32]. However, up till today such screening/surveillance had not taken place yet in Bhutan in spite the high prevalence of *H. pylori* infection and high GC rate among all age groups.

The current study revealed that 95% of GC patients were diagnosed at stages 3 and 4 and accordingly this could result in a higher mortality than early diagnosis. Early cancer detection is important because countries that perform GC surveillance, such as Japan and Korea, have lower mortality rates[33]. The Asian-Pacific Consensus Group recommended the screening and treatment of *H. pylori* as an evidenced-based and reasonable strategy for primary prevention of GC in selected communities where the burden of GC is high[32].

It has been well documented that treatment of *H. pylori* infection has an impact on the precursors of GC. A study from Colombia, a region with high GC risk, assessed the effect of *H. pylori* eradication therapy on intestinal metaplasia, multifocal atrophy and dysplasia in reported significant regression in histopathology score after treatment[33-36]. A recent study from Taiwan reported that mass eradication of *H. pylori* infection resulted in significant reduction in incidence of gastric atrophy resulting from chemoprevention[37]. Adopting the 2008 Asia-Pacific guidelines for a low threshold for treatment of symptomatic patients, as well as low cost follow-up testing could significantly lower the prevalence of peptic ulcer disease, GC. Therefore, there it is a great need for developing surveillance and prevention strategies for GC in Bhutan.

The utilization of the current data for constructing our study has some shortcomings that should be addressed. The main limitation is that we relied on the hospital records and not GC registry to identify the cancer cases. However, up till today, there is no cancer registry in Bhutan and the Thimphu National hospital is the only hospital that diagnoses all cancer cases in the country, so our data is valid as representative GC cases in Bhutan. The second limitation of the study that we did not have enough data to calculate the overall mortality rate due GC and further studies are highly needed to address that topic.

In conclusion, this study demonstrates clear evidence of the high GC incidence in Bhutan that could be attributed to the high prevalence of *H. pylori* infection that we previously reported. The lowest incidence of GC in Southern part of the country could be due to the difference in the ethnicity as most of its population is of Indian and Nepal origin. Our current study emphasizes on the importance for developing surveillance and prevention strategies for GC in Bhutan.

**COMMENTS**

**Background**

The World Health Organization reports the incidence of gastric cancer (GC) in Bhutan to be very high; however there is no published data yet. GC is the second leading cause of cancer-related mortality and the fourth most common cancer globally. However, its incidence rates in different geographical regions are distinctly varied. It has been established that a *Helicobacter pylori* (H. pylori) infection is an etiologic agent of chronic gastritis and peptic ulcer disease, GC and mucosal associated lymphoid tissue lymphoma and it is listed as as a number one carcinogen.

**Research frontiers**

The authors performed a retrospective study on a cohort of patients estimate the incidence of GC in Bhutan and to compare the geographic distribution of GC to our previously reported geographic distribution of *H. pylori* infection.

**Innovations and breakthroughs**

The incidence rate of GC in Bhutan is twice as high in the United States but is likely an underestimate rate because of unreported and undiagnosed cases in the villages.

**Applications**

The high incidence of GC in Bhutan could be attributed to the high prevalence of *H. pylori* infection that the authors previously reported. The lowest incidence of GC in Southern part of the country could be due to the difference in the ethnicity as most of its population is of Indian and Nepal origin. It is of importance for developing surveillance and prevention strategies for GC in Bhutan.

**Peer-review**

This is an interesting and well written paper.

**REFERENCES**

1. Ang TL, Fock KM. Clinical epidemiology of gastric cancer. *Singapore Med J* 2014; 55: 621-628 [PMID: 25630323 DOI: 10.11622/smedj.2014174]
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010; 127: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Online]. Available from: URL: http://globocan.iarc.fr
4. Stomach cancer statistics. Stomach cancer is the fifth most common cancer in the world, with 952000 new cases diagnosed in
incidence among Japanese in Hawaii. Etnh Dis 2004; 14: 431-439 [PMID: 15328946]
21 Memra V, Misra SP, Dwivedi M, Singh PA. Point prevalence of peptic ulcer and gastric histology in healthy Indians with Helicobacter pylori infection. J Infect Dis 1997; 175: 1487-1491 [PMID: 9317609]
22 El-Emam EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lisowski J, Yoon CC, Rothman N, Lanyon G, Martin M, Fraumeni JF, Rabkin CS. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398-402 [DOI: 10.1038/35060811]
23 Peterson WL, Graham DY, Marshall B, Blaser MJ, Genta RM, Klein PD, Stratton CW, Drneck J, Prockocimer P, Siepman N. Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. J Am Gastroenterol 1993; 88: 1860-1864 [PMID: 8237933]
24 Graham DJ, Lew GM, Malaty HM, Evans DJ, Graham SD, Klein PD, Alpert LC, Genta RM. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102: 493-496 [PMID: 1732120]
25 Pounder RE, Williams MP. The treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 11 Suppl 1: 35-41 [DOI: 9146789 [PMID: 10467361.11.s1.9.x]]
26 Carlson SJ, Yokoo H, Vanagasus A. Progression of gastritis to monoclonal B-cell lymphoma with resolution and recurrence following eradication of Helicobacter pylori. JAMA 1996; 275: 937-939 [PMID: 8598622 DOI: 10.1001/jama.1996.03530360047037]
27 Moayyedi P, Dixon MF. Significance of Helicobacter pylori infection and gastric cancer: implications for screening. Gastrointest Endosc Clin N Am 1997; 7: 47-64 [PMID: 8995112]
28 Tanahashi T, Sutsumi Y, Sawaii N, Yamaoka Y, Nakanishi K, Kodama T, Kashima K. Regression of atypical lymphoid hyperplasia after eradication of Helicobacter pylori. J Gastroenterol Hepatol 1997; 23: 543-547 [PMID: 9290905 DOI: 10.1111/j.1365-2036.1997.tb00690.x]
29 Peterson WL, Fendrick AM, Cave DR, Peura DA, Garabedian-Raffalo SM, Laine L. Helicobacter pylori-related disease: guidelines for testing and treatment. Arch Intern Med 2000; 160: 1285-1291 [PMID: 10809031 DOI: 10.1001/archinte.160.9.1285]
30 Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13: 1-12 [PMID: 9737564 DOI: 10.1111/j.1440-1746.1998.tb00537.x]
31 Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers J. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-781 [PMID: 17170018 DOI: 10.1136/gut.2006.101634]
32 Fock KM, Talley NJ, Moayyedi P, Hunt R, Azuma T, Sugano K, Xiao SD, Lam SK, Koh KL, Chiba T, Uemura N, Kim JG, Kim K, Ang TL, Mahachai V, Mitchell H, Rani AA, Liou JM, Vilaichone RK, Sollano J. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 2008; 23: 351-365 [PMID: 18318820 DOI: 10.1111/j.1440-1746.2008.05314.x]
33 Leung WK, Lin SR, Ching JY, To KF, Ng EK, Chan FK, Lau JY, Sung JJ. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004; 53: 1244-1249 [PMID: 15306578 DOI: 10.1136/gut.2003.034629]
34 Rokkas T, Pitsiolas D, Sechopoulos P, Roberts I, Margaritis G. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter 2007; 12 Suppl 2: 32-38 [PMID: 17991174]
35 Wang J, Xu L, Shi R, Huang X, Li SW, Huang Z, Zhang G. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion 2011; 83: 253-260 [PMID: 21282951 DOI: 10.1159/000308318]
36 Uemura N, Mukai T, Okamoto S, Yamagushi S, Mashiba H, Taniyama K, Sasaki N, Haruna K, Sannai K, Kajiyama G. Effect of Helicobacter pylori eradication on subsequent development of
cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997; 6: 639-642 [PMID: 9264278]

Lee YC, Chen TH, Chiu HM, Shun CT, Chiang H, Liu TY, Wu MS, Lin JT. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut 2013; 62: 676-682 [PMID: 22698649 DOI: 10.1136/gutjnl-2012-302240]
